Made Scientific, a Princeton-based cell therapy Contract Development and Manufacturing Organization (CDMO), and Streamline Bio, a next-generation autonomous robotics company based in Massachusetts, announced a collaboration to accelerate the use of AI-driven precision robotics in cell therapy manufacturing.
The companies completed the initial validation of Streamline Bio’s robotics platform in a live cell therapy production environment at Made Scientific’s Princeton facility, paving the way for the integration of the fully robotic solution into Good Manufacturing Practice (GMP) cleanrooms for commercial-scale use.
Addressing bottlenecks in cell therapy
Streamline Bio’s platform directly addresses critical bottlenecks in the cell and gene therapy (CGT) industry, including manufacturing complexity, high costs, and variable product quality. The technology aims to provide a flexible alternative to rigid, infrastructure-heavy automation systems.
“Streamline Bio’s robotic platform allows cell and gene therapy developers and manufacturers to respond with automation that’s not only smart and scalable, but inherently adaptive,” Rodney Rietze, president & CEO of Streamline Bio said. This flexibility allows the system to integrate seamlessly across diverse equipment and protocols, minimizing the need for extensive process changes or custom configurations.
The automation of manual, labor-intensive steps is expected to reduce operator burden, mitigate human error, and decrease overall costs, allowing skilled personnel to focus on higher-value activities. Furthermore, the platform’s digital-first design enables full data traceability.
Advancing to commercial scale
In the next phase of the collaboration, the platform is being prepared for GMP deployment and integration with widely used cell therapy systems, including the Miltenyi CliniMACS Prodigy®, G-Rex®, and Fresenius-Kabi LOVO® systems.
This integration at Made Scientific’s facility will demonstrate the platform’s ability to orchestrate complex, multi-step workflows, setting the stage for broader commercial implementation. Future efforts will also explore automating analytical and quality control testing workflows.
“Streamline Bio is redefining manufacturing by offering an innovative, flexible and scalable platform aimed at making transformative therapies more accessible to patients,” Syed Husain, chairman & CEO of Made Scientific said. “We’re excited to partner together as the companies explore how their technology can ultimately impact cost, process and product reproducibility and time-to-clinic for emerging therapies.”
